{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:14:39Z","timestamp":1783736079510,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Global Medical Affairs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Phase 3, randomized, placebo-controlled DISCOVER-2 study enrolled adults (<jats:italic>N<\/jats:italic>\u2009=\u2009739) with active PsA despite standard therapies who were biologic\/Janus kinase inhibitor-naive. Patients were randomized 1:1:1 to guselkumab 100\u00a0mg every 4 weeks; guselkumab 100\u00a0mg at week 0, week 4, then every 8 weeks; or placebo. In this post hoc analysis, patients randomized to guselkumab were included and pooled (<jats:italic>N<\/jats:italic>\u2009=\u2009493). Longitudinal trajectories of achieving each MDA criterion through week 100 were derived using non-responder imputation. Time to achieve each criterion was estimated with Kaplan-Meier analysis. Multivariate regression for time to achieve each criterion (Cox regression) and achievement at week 100 (logistic regression) was used to identify contributing factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Continuous improvement across all MDA domains was shown over time. ~70% of patients achieved near remission in swollen joint count (SJC), Psoriasis Area and Severity Index (PASI), and enthesitis through week 100. Median times to achieve individual criteria differed significantly (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), with SJC\u2009\u2264\u20091 (20 weeks), PASI\u2009\u2264\u20091 (16 weeks), and \u2264\u20091 tender entheses (16 weeks) being faster than patient-reported criteria (pain\u2009\u2264\u200915 mm, patient global assessment of arthritis and psoriasis\u2009\u2264\u200920 mm, Health Assessment Questionnaire-Disability Index\u2009\u2264\u20090.5) and tender joint count\u2009\u2264\u20091. Higher baseline domain scores, older age, worse fatigue, and increased body mass index were significant predictors of longer time to achieve minimal levels of disease activity assessed via patient-reported criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Substantial proportions of guselkumab-treated patients achieved individual MDA criteria, each showing continuous improvement through week 100, although with distinct trajectories. Median times to achieve physician-assessed MDA criteria were significantly faster compared with patient-driven criteria. Identification of modifiable factors affecting the time to achieve patient-reported criteria has the potential to optimize the achievement and sustainability of MDA in the clinic via a multidisciplinary approach to managing PsA, involving both medical and lifestyle interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>NCT03158285.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration date<\/jats:title>\n                <jats:p>May 16, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-024-00375-w","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T04:31:09Z","timestamp":1707021069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study"],"prefix":"10.1186","volume":"8","author":[{"given":"Laura C.","family":"Coates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Shan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,4]]},"reference":[{"key":"375_CR1","first-page":"127","volume":"62","author":"DD Gladman","year":"1987","unstructured":"Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PsA)--an analysis of 220 patients. Q J Med. 1987;62:127\u201341.","journal-title":"Q J Med"},{"key":"375_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379. https:\/\/doi.org\/10.1038\/s41584-022-00798-0.","journal-title":"Nat Rev Rheumatol"},{"key":"375_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053.","journal-title":"Ann Rheum Dis"},{"key":"375_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345. https:\/\/doi.org\/10.1002\/art.1780230202.","journal-title":"Arthritis Rheum"},{"key":"375_CR5","doi-asserted-by":"publisher","first-page":"e016619","DOI":"10.1136\/bmjopen-2017-016619","volume":"7","author":"P Rahman","year":"2017","unstructured":"Rahman P, Zummer M, Bessette L, et al. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open. 2017;7:e016619. https:\/\/doi.org\/10.1136\/bmjopen-2017-016619.","journal-title":"BMJ Open"},{"key":"375_CR6","doi-asserted-by":"publisher","first-page":"e000415","DOI":"10.1136\/rmdopen-2016-000415","volume":"3","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Kavanaugh A, Coates LC, et al. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open. 2017;3:e000415. https:\/\/doi.org\/10.1136\/rmdopen-2016-000415.","journal-title":"RMD Open"},{"key":"375_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/acr.20162","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010;62:970\u20136. https:\/\/doi.org\/10.1002\/acr.20162.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"375_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965\u20139. https:\/\/doi.org\/10.1002\/acr.20155.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"375_CR9","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK Multicentre, open-label, randomised controlled trial. Lancet. 2015;386:2489\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(15)00347-5.","journal-title":"Lancet"},{"key":"375_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/acr.23537","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, Mease PJ, Gossec L, et al. Minimal disease activity among active psoriatic arthritis patients teated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018;70:1529\u201335. https:\/\/doi.org\/10.1002\/acr.23537.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"375_CR11","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s40744-021-00343-7","volume":"8","author":"E Lubrano","year":"2021","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. The climb towards minimal disease activity in psoriatic arthritis. Rheumatol Ther. 2021;8:1443\u201350. https:\/\/doi.org\/10.1007\/s40744-021-00343-7.","journal-title":"Rheumatol Ther"},{"key":"375_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3899\/jrheum.210006","volume":"49","author":"E Meer","year":"2022","unstructured":"Meer E, Thrastardottir T, Wang X, et al. Risk factors for diagnosis of psoriatic arthritis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis: a set of parallel case-control studies. J Rheumatol. 2022;49:53\u20139. https:\/\/doi.org\/10.3899\/jrheum.210006.","journal-title":"J Rheumatol"},{"key":"375_CR13","unstructured":"TREMFYA\u00ae (guselkumab). Highlights of prescribing information [cited 2020. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf."},{"key":"375_CR14","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/jdv.14868","volume":"32","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32:1111\u20139. https:\/\/doi.org\/10.1111\/jdv.14868.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"375_CR15","doi-asserted-by":"publisher","first-page":"e001457","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7:e001457. https:\/\/doi.org\/10.1136\/rmdopen-2020-001457.","journal-title":"RMD Open"},{"key":"375_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604\u201316. https:\/\/doi.org\/10.1002\/art.41553.","journal-title":"Arthritis Rheumatol"},{"key":"375_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-021-02554-3","volume":"23","author":"P Rahman","year":"2021","unstructured":"Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021;23:190. https:\/\/doi.org\/10.1186\/s13075-021-02554-3.","journal-title":"Arthritis Res Ther"},{"key":"375_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/acr.24046","volume":"72","author":"PS Helliwell","year":"2020","unstructured":"Helliwell PS, Deodhar A, Gottlieb AB, et al. Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional phase II trial. Arthritis Care Res. 2020;72:1579\u201388. https:\/\/doi.org\/10.1002\/acr.24046.","journal-title":"Arthritis Care Res"},{"key":"375_CR19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(20)30263-4.","journal-title":"Lancet"},{"key":"375_CR20","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1016\/s2665-9913(21)00105-3","volume":"3","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:e715\u2013723. https:\/\/doi.org\/10.1016\/s2665-9913(21)00105-3.","journal-title":"Lancet Rheumatol"},{"key":"375_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475\u201385. https:\/\/doi.org\/10.1002\/art.42010.","journal-title":"Arthritis Rheumatol"},{"key":"375_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","volume":"62","author":"LC Coates","year":"2023","unstructured":"Coates LC, Ritchlin CT, Gossec L, et al. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). 2023;62:606\u201316. https:\/\/doi.org\/10.1093\/rheumatology\/keac375.","journal-title":"Rheumatology (Oxford)"},{"key":"375_CR23","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"key":"375_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686\u201391. https:\/\/doi.org\/10.1002\/art.23568.","journal-title":"Arthritis Rheum"},{"key":"375_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica. 1978;157:238\u201344. https:\/\/doi.org\/10.1159\/000250839.","journal-title":"Dermatologica"},{"key":"375_CR26","unstructured":"Ramey DR, Fries JF et al. G. S,. Quality of Life and Pharmacoleconomics in Clinical Trials, 2nd edition, The Health Assessment Questionnaire 1995 -- Status and Review. Philadelphia: Lippincott-Raven Pub; 1996. 227\u2013237."},{"key":"375_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528\u201338. https:\/\/doi.org\/10.1002\/cncr.10245.","journal-title":"Cancer"},{"key":"375_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41687-019-0115-4","volume":"3","author":"D Cella","year":"2019","unstructured":"Cella D, Wilson H, Shalhoub H, et al. Content validity and psychometric evaluation of Functional Assessment of Chronic illness therapy-fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019;3:30. https:\/\/doi.org\/10.1186\/s41687-019-0115-4.","journal-title":"J Patient Rep Outcomes"},{"key":"375_CR29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936\u20139. https:\/\/doi.org\/10.1136\/ard.2006.065763.","journal-title":"Ann Rheum Dis"},{"key":"375_CR30","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jpsychires.2010.04.025","volume":"44","author":"JC Mundt","year":"2010","unstructured":"Mundt JC, Greist JH, Gelenberg AJ, et al. Feasibility and validation of a computer-automated Columbia-suicide severity rating scale using interactive voice response technology. J Psychiatr Res. 2010;44:1224\u20138. https:\/\/doi.org\/10.1016\/j.jpsychires.2010.04.025.","journal-title":"J Psychiatr Res"},{"key":"375_CR31","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/acr.24593","volume":"74","author":"A Wong","year":"2022","unstructured":"Wong A, Ye JY, Cook RJ, et al. Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis. Arthritis Care Res. 2022;74:1430\u20134. https:\/\/doi.org\/10.1002\/acr.24593.","journal-title":"Arthritis Care Res"},{"key":"375_CR32","doi-asserted-by":"publisher","unstructured":"Richette P, Vis M, Ohrndorf S, et al. Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naive population of patients with PsA. RMD Open. 2023;9. https:\/\/doi.org\/10.1136\/rmdopen-2022-002934.","DOI":"10.1136\/rmdopen-2022-002934"},{"key":"375_CR33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/annrheumdis-2022-eular.902","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Contre C, et al. POS1017 guselkumab provides continued improvement in key domains of psoriatic arthritis through 2 years. Ann Rheum Dis. 2022;81:818\u20139.","journal-title":"Ann Rheum Dis"},{"key":"375_CR34","doi-asserted-by":"publisher","first-page":"e002195","DOI":"10.1136\/rmdopen-2022-002195","volume":"8","author":"CT Ritchlin","year":"2022","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH, et al. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 2022;8:e002195. https:\/\/doi.org\/10.1136\/rmdopen-2022-002195.","journal-title":"RMD Open"},{"key":"375_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81:359\u201369. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220991.","journal-title":"Ann Rheum Dis"},{"key":"375_CR36","doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH et al. (2022) Stringent disease activity control at 2 years across psoriatic arthritis domains irrespective of baseline characteristics in patients treated with guselkumab: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study (abstract). Arthritis Rheumatol 74.","DOI":"10.1136\/annrheumdis-2023-eular.3238"},{"issue":"Suppl 1","key":"375_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/msc.1694","volume":"20","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskelet Care. 2022;20(Suppl 1):12\u2013S21. https:\/\/doi.org\/10.1002\/msc.1694.","journal-title":"Musculoskelet Care"},{"key":"375_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/rheumatology\/keaa343","volume":"60","author":"JE Pope","year":"2021","unstructured":"Pope JE, Rampakakis E, Movahedi M, et al. Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI). Rheumatology. 2021;60:717\u201327. https:\/\/doi.org\/10.1093\/rheumatology\/keaa343.","journal-title":"Rheumatology"},{"key":"375_CR39","doi-asserted-by":"publisher","first-page":"e061474","DOI":"10.1136\/bmjopen-2022-061474","volume":"12","author":"E Vallejo-Yague","year":"2022","unstructured":"Vallejo-Yague E, Burkard T, Micheroli R, et al. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12:e061474. https:\/\/doi.org\/10.1136\/bmjopen-2022-061474.","journal-title":"BMJ Open"},{"key":"375_CR40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74:813\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204448.","journal-title":"Ann Rheum Dis"},{"key":"375_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/TP.0000000000000581","volume":"99","author":"TR Srinivas","year":"2015","unstructured":"Srinivas TR, Ho B, Kang J, et al. Post hoc analyses: after the facts. Transplantation. 2015;99:17\u201320. https:\/\/doi.org\/10.1097\/TP.0000000000000581.","journal-title":"Transplantation"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-024-00375-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-024-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T04:32:08Z","timestamp":1707021128000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-024-00375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1186\/s41927-024-00375-w","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,4]]},"assertion":[{"value":"27 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The DISCOVER-2 study was conducted in accordance with the principles of the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. Each site\u2019s governing ethical body approved study protocols, and all patients provided written informed consent, as previously reported [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LCC: received grants\/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Medac, Novartis, Pfizer, and UCB. For manuscripts: LCC is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; meeting attendance\/travel support from Janssen; and research grants from Janssen and Novartis. PJM: received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, SUN, UCB, Ventyx; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. MS: Shareholder of Johnson & Johnson. Employee of Janssen Pharmaceutical Companies of Johnson & Johnson. ER: consultant of Janssen. Employee of JSS Medical Research. APK: shareholder of Johnson & Johnson. Employee of Janssen Research & Development, LLC. XLX: shareholder of Johnson & Johnson. Employee of Janssen Research & Development, LLC. SDC: employee of Janssen Scientific Affairs, LLC. Shareholder of Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. IBM: received consultant fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant\/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Roche, and UCB; and is a shareholder for Causeway Therapeutics, and Evelo Compugen. L-ST: consultant of AbbVie, Boehringer Ingelheim, Eli Lilly Janssen, Pfizer, and Sanofi. Grant\/research support from Amgen, Boehringer Ingelheim, Janssen, GlaxoSmithKline, Novartis, and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}